Treatment of Advanced HCC with Prior Liver Transplantation When Immunotherapy Is Contraindicated

This protocol addresses patients with advanced hepatocellular carcinoma, Child-Turcotte-Pugh A cirrhosis, and ECOG performance status 0–1, in whom immunotherapy-based regimens are contraindicated due to prior liver transplantation or a severe autoimmune disorder.

Clinical Scenario

Prior Liver Transplantation Severe Autoimmune Disorder Child-Turcotte-Pugh A ECOG PS 0–1

In patients with recurrent HCC after liver transplantation, immune checkpoint inhibitors carry an increased risk of graft loss and death, making this a distinct management population. Patients with Child-Turcotte-Pugh A cirrhosis who cannot receive atezolizumab plus bevacizumab or durvalumab plus tremelimumab — whether due to transplant history or severe autoimmune disorder — require a separate treatment pathway.

Treatment Approach (partial)

For eligible patients in this population, structured second-line systemic therapy is the recommended approach. Agent selection depends on individual clinical factors. The complete evidence-based regimen — including which agents apply and under what criteria — is available below.

Instant Access to Structured Evidence-Based Regimens

References

Patients with Child-Turcotte-Pugh A cirrhosis in whom atezolizumab plus bevacizumab and durvalumab plus tremelimumab are contraindicated should be offered first-line sorafenib or lenvatinib (Level 1, Strong Recommendation). DOI: 10.1097/HEP.0000000000000466
AASLD advises against the use of ICIs in patients with recurrent HCC after liver transplantation given increased risk of graft loss and death (Level 4, Strong Recommendation). DOI: 10.1097/HEP.0000000000000466
AASLD advises cabozantinib or regorafenib (or ramucirumab in patients with AFP ≥ 400 ng/ml) as preferred agents after sorafenib or lenvatinib if patients are not eligible for clinical trials (Level 1, Strong Recommendation). DOI: 10.1097/HEP.0000000000000466

View source ↗